ENGOT-OV62/NOGGO OV 53/N-Plus
Trial Description:
A Phase III randomized, open label study of NiraParib maintenance after
Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high
grade ovarian cancer patientS in first line therapy
Lead Cooperative Group:
Trial Number:
Disease Site:
Ovarian
Trial Status:
Pending
Contact person:
ebraicu